
# Predictors of Health-Related Quality of Life in Patients on Androgen Deprivation Therapy for **Metastatic Prostate Cancer**



3. University of Iowa Hospitals and Clinics Department of Internal Medicine – Hematology, Oncology, and Blood and Marrow Transplantation

### Introduction


- Castration is required for metastatic prostate cancer treatment
- Castration is accomplished by orchiectomy or androgen deprivation therapy (ADT)
- ADT is associated with worse adverse effects and lower quality of life (QOL) than orchiectomy
- We sought to identify predictors of poor QOL in a cohort of patients on ADT for metastatic prostate cancer



-7.44,-0.36


-19.80,1.60

-0.26,1.60



## **Methods**

- Prospective survey of patients receiving ADT at a single institution between January 2015 and April 2018
- Inclusion criteria: N1 or M1 prostate cancer currently receiving medical therapy
- 312 patients screened, 142 met criteria
- Mail-based survey
- QOL assessed using validated Functional Assessment of Cancer Therapy – Prostate (FACT-P)
- Also assessed bother from current treatment and understanding of alternatives
- Clinical and demographic details obtained by electronic chart review



### Morgan E. Schubbe<sup>1</sup>, Bradley A. Erickson<sup>1</sup>, Conrad M. Tobert<sup>1</sup>, Sarah Bell<sup>2</sup>, Rohan Garje<sup>3</sup>, Paul T. Gellhaus<sup>1</sup>

0.03

0.10

0.16

1. University of Iowa Hospitals and Clinics Department of Urology

2. University of Iowa Holden Comprehensive Cancer Center Biostatistics Core

- single institution
- surgical castration cohorts

Univariate analysis of factors associated with lower FACT-P score.

67

19

49

68

- Lower FACT-P scores associated with increased bother from ADT side effects and cosmetic changes to genitalia

- Patients with castrate resistant disease tend to report lower QOL scores, though

- Increased interval from localized to metastatic prostate cancer diagnosis may also be associated with lower QOL

- Overall, QOL is something we need to do better job of routinely assessing

- HRQOL of patients on ADT for metastatic prostate cancer is negatively impacted in patients bothered by side effects and those bothered by genital changes

#### **Limitations and Future Studies**

- This study involved a small cohort at a

Surveys are subject to recall bias

- Future studies include quality of life comparison between medical ADT and